Alnylam Pharmaceuticals, Inc. and Regeneron Pharmaceuticals, Inc. announced positive interim results from the ongoing single ascending dose part of the Phase 1 study of...
Regeneron Pharmaceuticals, Inc. and Sanofi announced that the European Commission (EC) has expanded the marketing authorization for Dupixent (dupilumab) in the European Union to...
Regeneron Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved the PD-1 inhibitor Libtayo (cemiplimab-rwlc) in combination with platinum-based chemotherapy...
